Fig. 1 · Structure

Documents & Downloads

Tropisetron (ICS 205930)

Cat. No. A11226 CAS 89565-68-4

5-HT3 antagonist

Tropisetron is a serotonin 5-HT3 receptor antagonist used mainly as an antiemetic to treat nausea and vomiting following chemotherapy.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
5-HT3 Receptor IC50 70.1 nM

Tropisetron (ICS 205930) Research Summary

This section summarizes 4 in vivo studies of Tropisetron (ICS 205930) from 3 published references. In vivo models include Tg AD mice.

Tropisetron (ICS 205930) In Vivo Studies

In rats with pilocarpine-induced epilepsy, Tropisetron notably reduced spontaneous recurrent seizure frequency compared with the epilepsy group. Tropisetron also decreased target-platform latency during visible-platform Morris water maze training in this model. In Tg AD mice, Tropisetron significantly decreased cortical and hippocampal Aβ levels compared with saline-treated controls. In rats undergoing trauma-hemorrhage and resuscitation, Tropisetron attenuated increases in plasma AST and ALT levels compared with vehicle-treated trauma-hemorrhage controls. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Tropisetron reduces spontaneous seizure frequency in epileptic rats

Animal study · Male Sprague–Dawley rats; pilocarpine‐induced epileptic rat model; n = 8 [1]

Male Sprague–Dawley rats with pilocarpine-induced epilepsy received Tropisetron by intraperitoneal injection at 3 mg/kg/day for 3 weeks following the onset of spontaneous recurrent seizures. Treatment notably reduced seizure frequency compared with the epilepsy group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
frequency, severity, and duration of spontaneous seizuresReported result 3 mg/kg/day for 3 weeks following the onset of spontaneous recurrent seizures (SRS): notably reduced the frequency of SRS; # p < 0.05, epilepsy versus epilepsy + tropisetron[1]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
daily; for 3 weeks following the onset of spontaneous recurrent seizures (SRS)
Vehicle
saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tropisetron 3 mg/kg/dayepilepsy group3 mg/kg/day for 3 weeks following the onset of spontaneous recurrent seizures (SRS): notably reduced the frequency of SRS; # p < 0.05, epilepsy versus epilepsy + tropisetron[1]
Tropisetron 3 mg/kg/day
Model: Male Sprague–Dawley rats; pilocarpine‐induced epileptic rat model; n = 8
Methods and source locations

Compound reported in the paper: Tropisetron

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Experimental Procedures > Animals (S1); Materials and Methods > Experimental Procedures > The Pilocarpine‐Induced Epileptic Rat Model (S4, S5, S6, S9); Materials and Methods > Experimental Procedures > Animal Grouping and Drug Treatment (S12, S16, S17); Materials and Methods > Monitoring of Spontaneous Recurrent Seizures (S23); Results > Tropisetron Exhibits Anti‐Epileptic Effect in TLE Rats (S79); FIGURE 1 legend (S159)

frequency, severity, and duration of spontaneous seizures: frequency, severity, and duration of spontaneous seizures; comparator: epilepsy group — Materials and Methods > Experimental Procedures > Animal Grouping and Drug Treatment (S17); Materials and Methods > Monitoring of Spontaneous Recurrent Seizures (S23); Results > Tropisetron Exhibits Anti‐Epileptic Effect in TLE Rats (S79); FIGURE 1 legend (S159)

Tropisetron 3 mg/kg/day · Materials and Methods > Experimental Procedures > Animal Grouping and Drug Treatment (S17); Results > Tropisetron Exhibits Anti‐Epileptic Effect in TLE Rats (S79); FIGURE 1 legend (S159)

Tropisetron decreases brain Aβ levels in Tg AD mice

Animal study · Tg AD mice (5.0–5.5-month-old) [2]

Tg AD mice received Tropisetron intraperitoneally at 0.5 mg/kg/day for 8 consecutive weeks. Immunoblot analysis showed a significant decrease in cortical and hippocampal Aβ levels compared with saline-treated Tg AD controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Immunoblot analysisReported result 0.5 mg/kg/day for 8 consecutive weeks: a significant decrease in Aβ levels in cortex and hippocampus of tropisetron-treated Tg AD mice compared with Tg-AD controls[2]

Conditions shared by the study groups

Route
intraperitoneally injected
Treatment course
for 8 consecutive weeks
Vehicle
sterile normal saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tropisetron 0.5 mg/kg/dayNS-treated Tg AD groups (n = 8)0.5 mg/kg/day for 8 consecutive weeks: a significant decrease in Aβ levels in cortex and hippocampus of tropisetron-treated Tg AD mice compared with Tg-AD controls[2]
Tropisetron 0.5 mg/kg/day
Model: Tg AD mice (5.0–5.5-month-old)
Methods and source locations

Compound reported in the paper: Tropisetron

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Chronic tropisetron treatment (S14, S15, S16); Results > Chronic tropisetron treatment diminishes Aβ plaque levels and mitigates glial activation and neuroinflammation in Tg AD mice (S104)

Immunoblot analysis: Immunoblot analysis; comparator: NS-treated Tg AD groups (n = 8) — Methods > Chronic tropisetron treatment (S16); Results > Chronic tropisetron treatment diminishes Aβ plaque levels and mitigates glial activation and neuroinflammation in Tg AD mice (S104)

Tropisetron 0.5 mg/kg/day · Methods > Chronic tropisetron treatment (S16); Results > Chronic tropisetron treatment diminishes Aβ plaque levels and mitigates glial activation and neuroinflammation in Tg AD mice (S104)

Tropisetron and Plasma AST and ALT After Trauma-Hemorrhage

Animal study · male Sprague-Dawley rats; trauma-hemorrhage; n = 8 rats in each group [3]

Male Sprague-Dawley rats undergoing trauma-hemorrhage and resuscitation received intravenous Tropisetron. Treatment attenuated the trauma-hemorrhage-induced increase in plasma AST and ALT levels compared with the trauma-hemorrhage vehicle group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
plasma AST and ALT levelsReported result Tropisetron (1 mg/kg) treatment attenuated the trauma-hemorrhage-induced increase in plasma AST and ALT levels.[3]

Conditions shared by the study groups

Route
intravenously
Treatment course
Thirty minutes before the end of the resuscitation period
Vehicle
about 0.2 mL, 10% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tropisetron 1 mg/kgan equal volume of the vehicleTropisetron (1 mg/kg) treatment attenuated the trauma-hemorrhage-induced increase in plasma AST and ALT levels.[3]
Tropisetron 1 mg/kg
Model: male Sprague-Dawley rats; trauma-hemorrhage; n = 8 rats in each group
Methods and source locations

Compound reported in the paper: Tropisetron

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Experimental Groups (S8, S9); Materials and Methods > Rat Trauma-Hemorrhagic Shock Model (S15, S23); Results > Alteration of Plasma AST and ALT Levels (S58); Figure 2 legend (S91)

plasma AST and ALT levels: plasma AST and ALT levels; comparator: an equal volume of the vehicle — Results > Alteration of Plasma AST and ALT Levels (S58)

Tropisetron 1 mg/kg · Materials and Methods > Experimental Groups (S9); Materials and Methods > Rat Trauma-Hemorrhagic Shock Model (S23); Results > Alteration of Plasma AST and ALT Levels (S58)

Tropisetron decreases platform latency in epileptic rats

Animal study · Male Sprague–Dawley rats; pilocarpine‐induced epileptic rat model; n = 8 [1]

Male Sprague–Dawley rats with pilocarpine-induced epilepsy received Tropisetron by intraperitoneal injection at 3 mg/kg/day for 3 weeks following the onset of spontaneous recurrent seizures. Treatment decreased latency to reach the target platform during visible-platform Morris water maze training compared with the epilepsy group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The latency to reach the underwater platform was evaluated using the Morris water mazeReported result 3 mg/kg/day for 3 weeks following the onset of spontaneous recurrent seizures (SRS): During the visible platform training, tropisetron decreased the latency to reach the target platform during the 5‐day training trials; # p < 0.05, epilepsy versus epilepsy + tropisetron[1]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
daily; for 3 weeks following the onset of spontaneous recurrent seizures (SRS)
Vehicle
saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tropisetron 3 mg/kg/dayepilepsy group3 mg/kg/day for 3 weeks following the onset of spontaneous recurrent seizures (SRS): During the visible platform training, tropisetron decreased the latency to reach the target platform during the 5‐day training trials; # p < 0.05, epilepsy versus epilepsy + tropisetron[1]
Tropisetron 3 mg/kg/day
Model: Male Sprague–Dawley rats; pilocarpine‐induced epileptic rat model; n = 8
Methods and source locations

Compound reported in the paper: Tropisetron

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Experimental Procedures > Animals (S1); Materials and Methods > Experimental Procedures > The Pilocarpine‐Induced Epileptic Rat Model (S4, S5, S6, S9); Materials and Methods > Experimental Procedures > Animal Grouping and Drug Treatment (S12, S16, S17); Results > Tropisetron Exhibits Anti‐Epileptic Effect in TLE Rats (S82); FIGURE 1 legend (S160)

The latency to reach the underwater platform was evaluated using the Morris water maze: The latency to reach the underwater platform was evaluated using the Morris water maze; comparator: epilepsy group — Materials and Methods > Experimental Procedures > Animal Grouping and Drug Treatment (S17); Results > Tropisetron Exhibits Anti‐Epileptic Effect in TLE Rats (S82); FIGURE 1 legend (S160)

Tropisetron 3 mg/kg/day · Materials and Methods > Experimental Procedures > Animal Grouping and Drug Treatment (S17); Results > Tropisetron Exhibits Anti‐Epileptic Effect in TLE Rats (S82); FIGURE 1 legend (S160)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 89565-68-4
Applications 5-HT3 antagonist
Formula C17H20N2O2
Molecular Weight 284.35
Synonyms Novaban; ICS 205930
SMILES
CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1c[nH]c3ccccc13)C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 9 mg/mL (31.64 mM)
Water 48 mg/mL (168.81 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tropisetron (ICS 205930) Research References

  1. [1] Qian X, Sheng X, Ding J, et al. Tropisetron, an Antiemetic Drug, Exerts an Anti-Epileptic Effect Through the Activation of α7nAChRs in a Rat Model of Temporal Lobe Epilepsy. CNS Neurosci Ther (2024). PMID: 39445711 DOI: 10.1111/cns.70086 Source material
  2. [2] Liu LF, Liu YT, Wu DD, et al. Inhibiting 5-hydroxytryptamine receptor 3 alleviates pathological changes of a mouse model of Alzheimer's disease. Neural Regen Res (2023). PMID: 36926728 DOI: 10.4103/1673-5374.366492 Source material
  3. [3] Liu FC, Yu HP, Hwang TL, et al. Protective effect of tropisetron on rodent hepatic injury after trauma-hemorrhagic shock through P38 MAPK-dependent hemeoxygenase-1 expression. PLoS One (2012). PMID: 23285267 DOI: 10.1371/journal.pone.0053203 Source material

Added to your cart

View Cart Checkout
Loading...